Compare UBXG & HOTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UBXG | HOTH |
|---|---|---|
| Founded | 2018 | 2017 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 66.0M | 18.0M |
| IPO Year | 2024 | 2019 |
| Metric | UBXG | HOTH |
|---|---|---|
| Price | $2.04 | $0.98 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.50 |
| AVG Volume (30 Days) | 12.5K | ★ 139.9K |
| Earning Date | 12-22-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $29,674,534.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.62 | $0.66 |
| 52 Week High | $4.64 | $3.80 |
| Indicator | UBXG | HOTH |
|---|---|---|
| Relative Strength Index (RSI) | 46.72 | 31.57 |
| Support Level | $1.93 | $1.06 |
| Resistance Level | $2.05 | $1.12 |
| Average True Range (ATR) | 0.12 | 0.05 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 26.04 | 3.81 |
U-BX Technology Ltd focuses on providing value-added services using artificial intelligence-driven technology to businesses in the insurance industry, including insurance carriers and brokers. Its main offerings include three services/products: digital promotion services, risk assessment services, and value-added bundled benefits. The PRC operating entities help their institutional clients gain visibility on various social media platforms and generate revenue based on consumers' clicks, views, or clients' promotion time on these channels. U-BX Beijing developed a unique algorithm named the Magic Mirror. The majority of revenue comes from digital promotion services. Geographically, all of the company's revenue is derived from Mainland China.
Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA).